Trevi Therapeutics
14
2
2
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 14 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
75%
9 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
NAL ER IPF Respiratory Function and Safety Study
Role: lead
Refractory Chronic Cough Improvement Via NAL ER (RIVER)
Role: lead
A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants
Role: lead
Study of Nalbuphine ER in Participants With Hepatic Impairment
Role: lead
A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants
Role: lead
Cough Reduction in IPF With Nalbuphine ER
Role: lead
PRISM Study-Pruritus Relief Through Itch Scratch Modulation
Role: lead
A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough
Role: lead
Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Role: lead
Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus
Role: lead
Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis
Role: lead
Oral Abuse Potential Study of Nalbuphine
Role: lead
Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis
Role: lead
Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus
Role: lead
All 14 trials loaded